Ipratropium bromide treatment of experimental rhinovirus infection

Experimental Human Rhinovirus Infection

Double-blind trials were conducted in volunteers to evaluate the efficacy of the prophylactic 3,4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA) treatment against rhinovirus type 24 challenge. Ten men received a 7-day course of DIQA treatment and 11 men received a placebo. The intranasal viral challenge dose was 10 mean tissue culture infective doses. The oral administration of 1 g precha...

Ipratropium bromide bronchodilator solution.

Experimental rhinovirus infection in volunteers.

Experimental viral disease studies in volunteers have clarified many aspects of the pathogenesis of human viral disease. Recently, interest has focused on rhinovirus-associated asthma exacerbations, and new volunteer studies have suggested that airway responsiveness (AR) is enhanced during a cold. For scientific, ethical and safety reasons, it is important to use validated methods for the prepa...

Ineffectiveness of ipratropium bromide in acute bronchiolitis.

In a double blind randomised trial, we found no evidence that nebulised ipratropium bromide was of clinical benefit in acute bronchiolitis.

Effects of Inhaled Albuterol and Ipratropium Bromide

Study objective: Systemic administration of P-agonist and anticholinergic drugs markedly impair normal autonomic heart rate control. The purpose of this study was to quantify and compare the effects of therapeutic doses of inhaled albuterol and ipratropium on autonomic control of the cardiovascular system. Design: Randomized, double-blind, placebo-controlled, crossover design study. Setting: Te...